@article{e636257ac56d4806847ece588a8e6219,
title = "In Vitro Activity of a Hypochlorous Acid-Generating Electrochemical Bandage against Yeast Biofilms",
abstract = "The antibiofilm activity of a hypochlorous acid (HOCl)-producing electrochemical bandage (e-bandage) was assessed against 14 yeast isolates in vitro. The evaluated e-bandage was polarized at 11.5 VAg/AgCl to allow continuous production of HOCl. Time-dependent decreases in the biofilm CFU counts were observed for all isolates with e-bandage treatment. The results suggest that the described HOCl-producing e-bandage could serve as a potential alternative to traditional antifungal wound biofilm treatments.",
keywords = "antibiofilm, electrochemical bandage, hypochlorous acid, membrane biofilm, wound infections",
author = "Joseph Kletzer and Raval, {Yash S.} and Abdelrhman Mohamed and Mandrekar, {Jayawant N.} and Greenwood-Quaintance, {Kerryl E.} and Haluk Beyenal and Robin Patel",
note = "Funding Information: This research was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under the grant number R01 AI091594. The content presented in this work is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. H.B. holds a patent (US20180207301A1), “Electrochemical reduction or prevention of infections,” which refers to the electrochemical scaffold and bandage described herein. R.P. reports grants from ContraFect, TenNor Therapeutics Limited, and BioFire. R.P. is a consultant to Curetis, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, Torus Biosystems, Day Zero Diagnostics, Mammoth Biosciences, and Qvella; monies are paid to Mayo Clinic. Mayo Clinic and R.P. have a relationship with Pathogenomix. R.P. has research supported by Adaptive Phage Therapeutics. Mayo Clinic has a royalty-bearing know-how agreement and equity in Adaptive Phage Therapeutics. R.P. is also a consultant to Netflix, Abbott Laboratories, and CARB-X. In addition, R.P. has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an antibiofilm substance issued. R.P. receives honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course. J.K. contributed to experimental design, performed the e-bandage experiments in the agar biofilm model, and wrote the initial manuscript draft. Y.S.R. contributed to experimental design and performed the e-bandage experiments in the agar biofilm model. A.M. designed and built the wearable potentiostats and e-bandages and contributed to the experimental design. J.N.M performed a statistical analysis of the experimental data. K.E.G.-Q. contributed to the experimental design. H.B. and R.P. contributed to the experimental design and supervised the research project. Funding Information: This research was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under the grant number R01 AI091594. The content presented in this work is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: Copyright {\textcopyright} 2022 American Society for Microbiology. All Rights Reserved. Address correspondence to Robin Patel, patel.robin@mayo.edu. The authors declare a conflict of interest. H.B. holds a patent (US20180207301A1) “Electrochemical reduction or prevention of infections” which refers to the electrochemical scaffold and bandage described herein. R.P. reports grants from ContraFect, TenNor Therapeutics Limited, and BioFire. R.P. is a consultant to Curetis, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, Torus Biosystems, Day Zero Diagnostics, Mammoth Biosciences, and Qvella; monies are paid to Mayo Clinic. Mayo Clinic and R.P. have a relationship with Pathogenomix. R.P. has research supported by Adaptive Phage Therapeutics. Mayo Clinic has a royalty-bearing know-how agreement and equity in Adaptive Phage Therapeutics. R.P. is also a consultant to Netflix, Abbott Laboratories, and CARB-X. In addition, R.P. has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. R.P. receives honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course. Received 25 August 2022 Returned for modification 13 October 2022 Accepted 20 November 2022 Published 6 December 2022 Publisher Copyright: {\textcopyright} 2022 American Society for Microbiology. All Rights Reserved.",
year = "2023",
month = jan,
doi = "10.1128/aac.01166-22",
language = "English (US)",
volume = "67",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",
}